Upstream Bio Inc

UPB remains entrenched in a Stage 4 decline with price trading below its key moving averages. Medium-term bias is bearish, reinforced by a series of lower highs and lower lows and dynamic resistance at the 9/21 EMAs. Despite extreme oversold readings, recent rallies into EMAs have been rejected, supporting a Sell Now posture. A break and hold above the 21 EMA would invalidate this bearish timing edge.

• ↑TipRanks 'Strong Buy' PT $42.33 implies ~462% upside from $7.51
• ↑13F ownership high signals institutional confidence in UPB
• ↓Earnings yield –3.95% and negative profitability raise distress